Abstract
The renin-angiotensin system (RAS) and kallikrein-kinin system (KKS) are complex pathways linked by a number of molecules that participate in both systems. Apart from modulating a variety of normal physiological processes, both the RAS and KKS are up-regulated following tissue injury where they influence vascular function, inflammation, cell growth and differentiation and angiogenesis. The RAS exerts its effects by the generation of a family of bioactive angiotensin peptides in which angiotensin II (ANG II) and the angiotensin type 1 (AT1) and angiotensin type 2 (AT2) receptors are most well characterised. In the KKS, bradykinin (BK) and kallidin and their carboxypeptidase metabolites, des-Arg9-BK and des-Arg10-kallidin, are the effector peptides exerting their actions via BK type 1 (BK-B1) and BK type 2 (BK-B2) receptors. Emerging evidence suggests that an ocular RAS is activated in diabetic retinopathy and may contribute to progressive alterations to retinal cells such as pericytes, endothelial cells, neurons and glia. Less well studied is the retinal KKS, however recent studies indicate effects on retinal electrophysiology and angiogenesis. The pathogenetic actions of the RAS and KKS in many tissues and possibly the diabetic retina are mediated by specific growth factors such as vascular endothelial growth factor (VEGF) and connective tissue growth factor (CTGF). This review will examine the roles of the RAS and KKS in both retinal vascular and neuro-glial dysfunction in diabetic retinopathy, and the potential of blockade of these systems for the prevention and treatment of this serious diabetic complication.
Keywords: angiotensin, bradykinin, retina, diabetes, neurons, glia, angiogenesis, vegf
Current Pharmaceutical Design
Title: Angiotensin and Bradykinin: Targets for the Treatment of Vascular and Neuro-Glial Pathology in Diabetic Retinopathy
Volume: 10 Issue: 27
Author(s): Jennifer L. Wilkinson-Berka and Erica L. Fletcher
Affiliation:
Keywords: angiotensin, bradykinin, retina, diabetes, neurons, glia, angiogenesis, vegf
Abstract: The renin-angiotensin system (RAS) and kallikrein-kinin system (KKS) are complex pathways linked by a number of molecules that participate in both systems. Apart from modulating a variety of normal physiological processes, both the RAS and KKS are up-regulated following tissue injury where they influence vascular function, inflammation, cell growth and differentiation and angiogenesis. The RAS exerts its effects by the generation of a family of bioactive angiotensin peptides in which angiotensin II (ANG II) and the angiotensin type 1 (AT1) and angiotensin type 2 (AT2) receptors are most well characterised. In the KKS, bradykinin (BK) and kallidin and their carboxypeptidase metabolites, des-Arg9-BK and des-Arg10-kallidin, are the effector peptides exerting their actions via BK type 1 (BK-B1) and BK type 2 (BK-B2) receptors. Emerging evidence suggests that an ocular RAS is activated in diabetic retinopathy and may contribute to progressive alterations to retinal cells such as pericytes, endothelial cells, neurons and glia. Less well studied is the retinal KKS, however recent studies indicate effects on retinal electrophysiology and angiogenesis. The pathogenetic actions of the RAS and KKS in many tissues and possibly the diabetic retina are mediated by specific growth factors such as vascular endothelial growth factor (VEGF) and connective tissue growth factor (CTGF). This review will examine the roles of the RAS and KKS in both retinal vascular and neuro-glial dysfunction in diabetic retinopathy, and the potential of blockade of these systems for the prevention and treatment of this serious diabetic complication.
Export Options
About this article
Cite this article as:
Wilkinson-Berka L. Jennifer and Fletcher L. Erica, Angiotensin and Bradykinin: Targets for the Treatment of Vascular and Neuro-Glial Pathology in Diabetic Retinopathy, Current Pharmaceutical Design 2004; 10 (27) . https://dx.doi.org/10.2174/1381612043383179
DOI https://dx.doi.org/10.2174/1381612043383179 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Impact of Diabetes on Cardiac and Vascular Disease: Role of Calcium Signaling
Current Medicinal Chemistry Cell Cycle Re-Entry in Alzheimers Disease: A Major Neuropathological Characteristic?
Current Alzheimer Research Conventional and Non-Conventional Targets of Natural Products in the Management of Diabetes Mellitus and Associated Complications
Current Medicinal Chemistry Computer-Aided Drug Design for AMP-Activated Protein Kinase Activators
Current Computer-Aided Drug Design Biomarkers and Future Targets for Development in Amyotrophic Lateral Sclerosis
Current Medicinal Chemistry β-Glucans: Old Molecules with Newly Discovered Immunological Activities
Drug Design Reviews - Online (Discontinued) Editorial (Thematic Issue: Endothelium: A Target for Therapeutic Intervention)
Current Vascular Pharmacology Aging and Proteins: What Does Proteostasis Have to Do with Age?
Current Molecular Medicine Advanced Glycation and ROS: A Link between Diabetes and Heart Failure
Current Vascular Pharmacology PET Radioligands for In Vivo Visualization of Neuroinflammation
Current Pharmaceutical Design Metabotropic Glutamate Receptors and Interacting Proteins in Epileptogenesis
Current Neuropharmacology Effects of ACE-Inhibitors and Angiotensin Receptor Blockers on Inflammation
Current Pharmaceutical Design Brain Oxidative Stress - Analytical Chemistry and Thermodynamics of Glutathione and NADPH
Current Topics in Medicinal Chemistry The Therapeutic Potential of RNA Interference: Novel Approaches for Cancer Treatment
Current Pharmaceutical Biotechnology Editorial
Current Diabetes Reviews Hypoglycaemia and Cardiovascular Disease Risk in Patients with Diabetes
Current Pharmaceutical Design Neurodegenerative Disease: A Perspective on Cell-Based Therapy in the New Era of Cell-Free Nano-Therapy
Current Pharmaceutical Design Perspectives and New Aspects of Metalloproteinases’ Inhibitors in the Therapy of CNS Disorders: From Chemistry to Medicine
Current Medicinal Chemistry Aggresome Formation and Neurodegenerative Diseases: Therapeutic Implications
Current Medicinal Chemistry Glycemic Variability, Oxidative Stress, and Impact on Complications Related to Type 2 Diabetes Mellitus
Current Diabetes Reviews